SPOTLIGHT: FDA approves Noxafil

The FDA has approved Noxafil, Schering-Plough's therapy for preventing fungal infections in leukemia patients. The infections-candida and aspergillus-are the leading cause of death among leukemia patients receiving chemotherapy or stem cell transplant therapies. Report

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.